Brexafemme

Active Ingredient(s): Ibrexafungerp Citrate
FDA Approved: * June 1, 2021
Pharm Company: * SCYNEXIS
Category: Antifungal

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Brexafemme Overview

Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection).[1] It is taken by mouth.[1] Ibrexafungerp is a triterpenoid antifungal.[1] Ibrexafungerp was approved for medical use in the United States in June 2021.[1][2] It is the first approved drug in a novel antifungal class.[2] Contents 1 Medical uses 2...

Read more Brexafemme Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ibrexafungerp

Recent Brexafemme Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ibrexafungerp Citrate
  • Tablet: 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ibrexafungerp Citrate or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 July 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA